Crikzo (Crizotinib) 250 mg
Crikzo (Crizotinib 250 mg) is an oral targeted therapy known as a Tyrosine Kinase Inhibitor (TKI).
Manufacturer: Hetero Healthcare (India). It is a generic version of Xalkori. Instead of killing all rapidly dividing cells like chemotherapy, Crikzo specifically targets cancer cells that harbor specific genetic mutations.
Mechanism of Action ("Signal Blocker"):
Crizotinib works by inhibiting the ALK (Anaplastic Lymphoma Kinase) or ROS1 proteins. In patients with these specific gene mutations, the protein acts like a stuck gas pedal, driving cancer growth. Crikzo blocks this protein, effectively taking the foot off the gas pedal, causing the tumor to stop growing or shrink.
โ Key Benefit: Significant improvement in progression-free survival for patients with specific genetic biomarkers.
Indicated for the treatment of:
- ๐ซ Non-Small Cell Lung Cancer (NSCLC): Advanced or metastatic stage.
- ๐งฌ Requirement: Tumors must be confirmed as ALK-positive or ROS1-positive via an FDA-approved test.
- It is not effective for patients without these specific mutations.
Packaging: 30 Capsules (250 mg each).
โ ๏ธ DOSAGE & ADMINISTRATION:
- ๐ Standard Dose: 250 mg taken orally twice daily (BID).
- ๐ฝ Intake: Swallow capsules whole. Can be taken with or without food. Do not crush or chew.
- Grapefruit and grapefruit juice should be avoided during treatment as they increase drug levels in the blood.
- Pregnancy (can cause fetal harm) and breastfeeding.
- Congenital Long QT Syndrome.
- Severe renal or hepatic impairment.
- Hypersensitivity to Crizotinib.
Common side effects to be aware of:
- ๐ Visual Disturbances: Trails of light, flashes, or blurred vision (very common, usually mild).
- ๐คข Gastrointestinal: Nausea, diarrhea, vomiting, constipation.
- โค๏ธ Cardiac: Bradycardia (slow heart rate), QT prolongation.
- Edema (swelling) and elevated liver enzymes.
What Customers Say
No reviews yet
Your review can be the first!